Merck KGaA to buy Rapid Micro Biosystems at $0.75 per share
What's the deal? Merck KGaADealroom has a profile for this one. Try Dealroom →, based in Darmstadt, Germany, has agreed to acquire Rapid Micro Biosystems (Nasdaq: RPID), a Massachusetts-based developer of automated microbial quality-control technology, for $0.75 per share in an all-cash tender offer. The companies did not disclose the deal's aggregate value.
What each side does: Rapid Micro Biosystems makes the Growth Direct platform, which automates microbial quality-control testing for manufacturers of biologics, vaccines, cell and gene therapies, and sterile injectables. It will join Merck KGaA's Life Science business, which sells automation technologies for pharmaceutical manufacturing and quality control.
Why now? The two companies have worked together for roughly 18 months. "Over the past 18 months, we have built a strong partnership with Merck KGaA, Darmstadt, Germany, centered on a shared commitment to innovation and helping customers modernize and automate their quality-control workflows," said Robert Spignesi, Rapid Micro Biosystems' chief executive officer.
What's the endgame? The deal extends the Growth Direct platform's reach through Merck KGaA's global life sciences operations and customers, which already include many of the world's largest drugmakers. The technology is designed to replace manual testing with automated systems that deliver faster results and support regulatory compliance.
What changes for customers: Paolo Carli, head of Advanced Solutions at Merck KGaA's Life Science business, said the acquisition would strengthen its ability to supply automated quality-control tools. "Our customers need reliable results faster, more efficient quality-control workflows and robust data integrity to support regulatory compliance," he said.
The terms: Merck KGaA will acquire all outstanding shares through the tender offer, with closing expected in December 2026, subject to a minimum tender condition and customary requirements. Perella Weinberg PartnersDealroom has a profile for this one. Try Dealroom → is advising Rapid Micro Biosystems, with Goodwin ProcterDealroom has a profile for this one. Try Dealroom → providing legal counsel.
The signal: A large life sciences supplier absorbing a specialised automation vendor points to drugmakers' growing push to replace manual quality-control steps with faster, auditable systems — and to consolidate those tools under fewer vendors.
Read more: citybiz.co
Image credit: "200224-N-DA693-1051" by NavyMedicine, public domain (Public Domain Mark 1.0)